Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes
Authors' conclusion
This pooled analysis suggests that tirzepatide may improve cardiometabolic abnormalities and resolve MetS in individuals with type 2 diabetes.
Study context
- Population
- Individuals with T2DM
- Participants
- 7,805 individuals7 RCTs
- Comparison
- Tirzepatide vs placebo or standard antihyperglycemic agents
- Outcome
- Presence of cardiometabolic abnormalities (MetS components: elevated waist circumference, TG, BP, fasting blood glucose, decreased HDL-C), elevated BMI and MetS (≥3 abnormalities)
- Follow-up
- Weighted median treatment duration 41.0 weeks
Methodological details7 Phase 3 RCTs, inverse probability weighting, mixed-effects models
- 7 Phase 3 RCTs
- Inverse probability weighting
- Mixed-effects models
Pooled result
As reported in the abstract
weighted median 41.0 weeks
Tirzepatide vs Placebo or standard antihyperglycemic agentsOdds ratio (95% CI)
Decreased HDL-C (34% reduction)
0.66(0.52–0.84)
Elevated BMI (96% reduction)
0.04(0.02–0.08)
MetS (72% reduction)
0.28(0.24–0.33)
Further pooled results
Metabolic syndrome (MetS) resolution by subgroup
- Higher efficacy in age <65 vs ≥65 years
- P for interaction = 0.008
- Higher efficacy without vs with baseline SGLT2 inhibitor use
- P for interaction = 0.009
- Consistent across demographic and clinical subpopulations
Original publication
Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes. J Am Coll Cardiol. Published 30 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →